Cardiac angiosarcoma is a primary malignant tumor of the heart with endothelial differentiation, capable of forming abnormal vascular structures and diffusely infiltrating surrounding tissues. Its most characteristic location is the right atrial wall, from which the tumor may expand into the chamber, penetrate the myocardium and reach the pericardium, atrioventricular groove and great vessels. The fragility of the neoplastic vascular network explains the frequent presence of intratumoral hemorrhage, bloody effusion and hemorrhagic complications at secondary sites.
It is one of the main histological types of adult cardiac sarcoma. Many case series report male predominance and diagnosis in the fourth or fifth decade, although cases occur at widely differing ages. Its rarity, referral-center patient selection and changes in sarcoma classification make a single estimate of relative frequency uncertain. Establishing a cardiac primary requires integration of the dominant site, anatomical relationships and staging, excluding a primary angiosarcoma elsewhere with cardiac involvement.
The disease combines local invasion with a propensity for hematogenous spread. Diagnosis may follow seemingly ordinary pericarditis, recurrent effusion, respiratory symptoms or discovery of metastases. Negative pericardial cytology and initially preserved ventricular function may coexist with substantial disease. Suspicion therefore calls for a combined assessment of the atrial wall, pericardium, pulmonary circulation and systemic manifestations.
In most clinical presentations, no specific causal exposure can be identified. Endothelial origin describes tumor differentiation, whereas the initial steps of transformation at the cardiac site remain incompletely understood. Factors linked to angiosarcomas elsewhere, such as chronic lymphedema or particular environmental exposures, cannot be considered proven causes of the usual cardiac form. A history of thoracic radiotherapy remains relevant to sarcoma assessment but requires examination of the irradiated field, latency and prior disease.
A documented hereditary association concerns pathogenic variants in POT1, which encodes a shelterin-complex protein involved in telomere protection. Family studies of cardiac angiosarcoma have associated one variant with impaired telomere protection, abnormal elongation and chromosomal fragility. This mechanism offers a biological explanation for certain familial forms without accounting for the origin of every case. Distinguishing germline from somatic alterations requires appropriate counseling and confirmatory testing.
Genetic counseling is particularly relevant for younger patients, those with other personal tumors or families affected by angiosarcoma and malignancies compatible with predisposition. Tests must be selected and interpreted in the clinical context, distinguishing pathogenic variants from variants of uncertain significance. Identification of predisposition may change surveillance for patients and carrier relatives; it neither predicts disease with certainty in every relative nor justifies uniform programs regardless of gene and individual circumstances.
The neoplasm tends to form a broad-based mass, often poorly demarcated from the atrial wall. The surface and cut section may appear hemorrhagic, with necrotic regions and solid areas. Extension along the atrioventricular groove may involve the right coronary artery; spread toward the venae cavae, tricuspid valve or right ventricle affects venous return and intracardiac flow. Pericardial invasion may be nodular or diffuse, with an extracavitary component larger than examination of the atrial lumen alone would suggest.
Vascular growth is structurally disorganized. Irregular channels, atypical endothelial cells and poorly differentiated solid areas coexist within the same tumor, causing morphological and imaging heterogeneity. Tumor perfusion may be high in some portions and absent in others because of necrosis or thrombosis. This behavior explains why a limited biopsy may yield only blood, fibrin or devitalized tissue, and why biopsy target selection should precede the procedure.
Hematogenous dissemination frequently affects the lungs but may involve the liver, bones, brain and other sites. Metastases retain vascular and hemorrhagic potential. Brain involvement deserves attention even in predominantly right-sided cardiac tumors: metastatic distribution of an infiltrating neoplasm cannot be reduced to the mechanical path of a single intracavitary embolus. Local and systemic spread must therefore be assessed simultaneously.
A right atrial mass reduces functional chamber volume and may obstruct caval inflow and tricuspid filling. Increased systemic venous pressure causes right-sided congestion, while reduced forward flow may impair cardiac output. Tricuspid invasion causes obstruction, regurgitation or both. Ventricular involvement adds contractile dysfunction; coronary involvement can cause ischemia even without significant atherosclerosis.
Pericardial effusion results from infiltration, impaired drainage and bleeding. When intrapericardial pressure exceeds chamber filling capacity, tamponade develops. Rapid accumulation can cause instability at smaller volumes than a chronic effusion; clots and loculation may complicate drainage and echocardiographic interpretation. In advanced cases, invasion and necrosis may weaken the cardiac wall, with risk of rupture and hemopericardium.
Atrial infiltration, ischemia and conduction abnormalities promote arrhythmias. The tumor surface may be associated with thrombosis and pulmonary embolization of neoplastic or thrombotic material. In the lungs, metastatic spread may cause bleeding around nodules or alveolar hemorrhage, resulting in dyspnea and hemoptysis. Blood-loss anemia, inflammation and metabolic consumption contribute to fatigue; severe presentations may also involve coagulation abnormalities, making it difficult to balance thrombotic and bleeding risks.
Dyspnea may reflect effusion, reduced cardiac output, congestion or pulmonary disease. Chest pain and palpitations are common reasons for evaluation, whereas peripheral edema, abdominal distension and easy fatigability suggest right heart impairment. Fever, sweating and weight loss may accompany the neoplasm. Tamponade can be the initial manifestation and lead to drainage before the neoplastic origin of the effusion is recognized.
Recurrent effusion, particularly when bloody, must be interpreted alongside findings in the atrial wall and pericardium. Its hemorrhagic nature helps guide the differential but also occurs with other neoplasms, iatrogenic causes and various inflammatory conditions. Persistence despite treatment directed at pericarditis warrants renewed etiological assessment. A mass of the right free wall, infiltrative thickening or associated lung nodules makes suspicion of angiosarcoma more coherent.
The respiratory history addresses hemoptysis, cough, pleuritic pain and rapidly worsening oxygenation. New headache, vomiting, seizures or focal deficits may indicate brain metastases or hemorrhage and require urgent investigations. Previous cancer, radiotherapy, anticoagulant exposure, cardiac procedures and family history are also documented. Reviewing bleeding episodes helps both diagnosis and procedure selection.
Examination assesses venous pressure, peripheral perfusion and respiratory status. Jugular venous distension, hepatomegaly, edema and ascites may coexist with hypotension and tachycardia. Pulsus paradoxus and muffled heart sounds suggest tamponade in the appropriate context; a murmur may reflect tricuspid involvement. Pallor, bruising, neurological findings or signs of pleural effusion complete the assessment. An unstable patient requires immediate stabilization while diagnostic planning remains compatible with the urgency.
Echocardiography identifies the mass, attachment, intracavitary extent and effects on blood flow. It is essential to quantify effusion and tamponade physiology, assess the tricuspid valve and evaluate right-sided function. Regions of the free wall and extracardiac components may be incompletely visualized; transesophageal echocardiography further defines relationships when it offers a tangible advantage. Vascularity demonstrated using contrast techniques supports the perfused nature of the lesion but cannot alone distinguish malignancy from benignity.
Cardiac magnetic resonance imaging depicts growth through the wall, relationships with the pericardium and coronary arteries, and internal composition. Blood at different evolutionary stages changes T1 and T2 signals; edema, necrosis and solid tissue create additional differences. Perfusion and late enhancement are often heterogeneous. Cine imaging assesses flow obstruction and motion of involved structures. No single signal pattern is pathognomonic: diagnosis relies on combined findings and pathological confirmation.
Contrast-enhanced CT is particularly useful for mapping the venae cavae, coronary arteries, pericardium and mediastinum, and for searching for thoracic disease. An infiltrative, heterogeneously vascularized right atrial mass associated with effusion and lung lesions forms a suspicious constellation. Pulmonary nodules may be surrounded by ground-glass areas due to hemorrhage; however, infection, edema and other causes must also be considered. CT may first reveal the disease when respiratory symptoms predominate.
FDG PET/CT may help characterize disease distribution and metabolically active sites, especially when CT findings are indeterminate or a biopsy site must be selected. Preparation should reduce physiological myocardial uptake. Even with suitable preparation, tumor metabolism, inflammation and postprocedural changes may overlap; findings must be interpreted alongside anatomical imaging. The ability to identify viable biopsy targets may be more useful than a numerical uptake value alone.
Assessment includes complete blood count and coagulation studies, renal and hepatic function, electrolytes and cardiovascular parameters as indicated. Anemia, thrombocytopenia and consumption markers must be considered in relation to bleeding, cancer and treatment. Troponin and natriuretic peptides can document cardiac injury or stress without indicating a specific histological diagnosis. ECG and rhythm monitoring help detect arrhythmias or conduction disturbances and assess procedural risk.
Biopsy must provide a reliable diagnosis via the safest route. An accessible extracardiac deposit may provide representative tissue, but vascular metastases also carry hemorrhagic risk. Site selection considers location, perfusion, amount of tissue needed and the ability to control bleeding. Cardiac sampling requires image guidance, expertise and appropriate backup support; the proximity of the thin atrial wall and pericardium demands particular caution.
Pericardial cytology may be negative despite infiltration. The effusion sometimes contains mostly blood and reactive cells with little tumor-cell shedding. Drainage remains essential when hemodynamically indicated, and the material obtained warrants proper analysis; however, a nondiagnostic result must be interpreted alongside clinical probability. Samples consisting only of necrosis or thrombus call for reconsideration of the target, rather than being taken as proof of benignity.
Microscopy reveals irregular, anastomosing vascular channels lined by atypical cells, alternating with solid spindle-cell or epithelioid areas. Pleomorphism, mitotic activity, infiltrative growth, hemorrhage and necrosis support the diagnosis. Poorly differentiated areas may show little vascular formation and mimic other tumors. Broad sampling is therefore important for recognizing differentiation and documenting biological heterogeneity.
Endothelial immunohistochemistry relies on a marker panel, in which CD31 and the nuclear marker ERG are particularly useful; FLI1, CD34 and other markers may provide complementary evidence. The intensity and extent of staining vary, particularly in poorly differentiated areas. Cytokeratins may be expressed, especially in epithelioid forms, and do not automatically exclude a vascular neoplasm. Diagnosis requires concordance among immunophenotype, morphology and anatomical context.
The differential includes other sarcomas, metastatic carcinoma, mesothelioma, lymphoma and benign vascular tumors. Hemangioma may be highly perfused but has a different architecture and cellular and infiltrative behavior. Organized thrombus and inflammatory processes can also complicate a mass's appearance. Specialist review is particularly appropriate for small samples, epithelioid variants and nonspecific reports. Grade and proliferation indices describe biological features but cannot alone reliably predict an individual's outcome.
Local staging must establish how much tumor remains confined to the atrial wall, which structures are invaded and whether reconstruction after removal is possible. Relationships with the right coronary artery, tricuspid valve, ventricle, venae cavae and pericardium are documented. Easy separation of the intracavitary component does not guarantee clear margins within the wall. These findings distinguish potentially complete resection, procedures for mechanical relief and locally unresectable disease.
Systemic assessment looks for lung metastases and abdominal, nodal and skeletal involvement according to protocols and findings. A new small nodule is not necessarily a confirmed metastasis; its significance depends on the number, morphology, evolution and whether confirmation would change treatment objectives. Bone symptoms or equivocal findings call for targeted investigation. Assessment must also distinguish metastatic spread from tumor embolization and thromboembolism, which may coexist.
Because of the possibility of brain metastases, brain imaging should be considered when staging angiosarcoma even without symptoms; contrast-enhanced MRI is particularly useful for small lesions. Acute neurological symptoms instead require urgent investigation, often starting with CT to identify bleeding. The hemorrhagic risk of metastases must inform treatment and anticoagulation decisions. Subsequent surveillance is individualized, since available data do not establish a universally appropriate interval for every patient.
For tamponade, the priority is to restore cardiac filling through drainage performed in the most appropriate setting, with surgical management when location, clots or other characteristics require it. Recurrence may prompt procedures to control effusion and obtain pericardial tissue. Congestion, arrhythmias and hypoxemia are treated with consideration of the anatomical obstruction. The mere presence of a mass does not justify anticoagulation, which requires a defined thrombotic problem and individualized bleeding-risk assessment.
In localized disease, resection with negative margins is the main objective of local control when technically and functionally feasible. Surgery may require removal and reconstruction of the atrial wall, with procedures on the tricuspid valve, venae cavae, coronary artery or pericardium according to extent. Microscopic infiltration and proximity to vital structures make radical resection difficult. The specimen must be oriented for margin assessment; absence of gross residual tumor does not necessarily mean an R0 resection.
Preoperative treatment may be discussed in hemodynamically stable patients to reduce tumor size and improve resectability. The choice depends on the likelihood of response, risk of progression and time available before mechanical compromise develops. Cardiac experience comes mainly from selected series and requires planned reassessment. Benefit observed from multimodal treatment does not prove that the same sequence is optimal for every presentation.
Debulking may relieve severe obstruction in selected patients but pursues a different oncological objective from complete resection. In disseminated disease, the symptomatic benefit must be weighed against risks and possible delay of systemic treatment. Donor heart transplantation is not a standard strategy: possible occult spread and progression under immunosuppression severely limit its role, even when the mass appears confined to the heart.
Radiotherapy may be used for local control, selected residual disease or palliation. Planning accounts for cardiac and respiratory motion, doses to myocardium, coronary arteries, valves and thoracic organs, and any previous treatments. For brain metastases or other symptomatic sites, surgery and irradiation are discussed according to number, size, bleeding, symptoms and systemic control. Clinical radiosensitivity and local benefit must be assessed case by case, avoiding the assumption that all sarcomas are uniformly radioresistant.
Weekly paclitaxel is one active option for advanced angiosarcoma. The phase II ANGIOTAX study of 30 patients with unresectable or metastatic angiosarcoma at different sites documented antitumor activity and contributed to its clinical use. This is histology-based evidence, not a randomized trial dedicated to cardiac disease. Selection considers neuropathy, marrow reserve, performance status, previous treatments and the need for a rapid response.
Anthracyclines, alone or in suitable combinations, are another option. Adding ifosfamide may be considered when tumor reduction is a priority and the patient can tolerate greater toxicity. In an infiltrated heart, dysfunction caused by the tumor must be distinguished from additional drug-related risk. Impaired function requires cardio-oncology discussion of alternatives, protective strategies and monitoring; cardiac location does not automatically preclude all anthracycline use.
In subsequent lines, gemcitabine-based treatments and other active sarcoma regimens, or targeted drugs such as pazopanib when indicated, may be considered. Choices depend on histology-specific evidence, previous exposures and toxicity profile. For inhibitors of angiogenic pathways, hypertension, cardiac dysfunction, thrombotic or bleeding risk and wound healing must be assessed. The vascular nature of the tumor provides a research rationale but does not guarantee response to an antiangiogenic agent.
Immunotherapy and certain targeted combinations are under investigation in angiosarcoma. Findings from cutaneous subgroups, which may have different genomic characteristics, require caution before application to primary cardiac disease. A treatment proposal should be supported by relevant biomarkers, authorized indications or access to a trial. Molecular profiling can be useful when it guides a concrete decision, distinguishing biologically interesting changes from targets with documented clinical efficacy.
Adjuvant treatment after resection is discussed according to margins, extent, previous therapy and systemic risk; no specific regimen has been universally validated for cardiac angiosarcoma. In advanced disease, goals include controlling progression, preventing complications and relieving symptoms. Supportive care addresses pain, dyspnea, anemia and nutritional deficits and accompanies cancer treatment from the earliest stages, with intensity matched to needs.
Cardio-oncology monitoring includes baseline assessment and treatment-adapted follow-up using echocardiography, ECG and biomarkers when appropriate. Blood pressure, rhythm, ventricular function and effusion are compared with baseline. Pharmacological cardioprotection or modification of the antineoplastic formulation must be individualized. New dyspnea requires distinguishing progression, tamponade, embolism, pulmonary hemorrhage, infection and toxicity: the presence of one known cause does not exclude a second complication.
Prognosis is generally poor because of the combination of late diagnosis, infiltration and early dissemination. Reviews of case series describe highly variable, often limited survival, although some patients achieve more prolonged control after multimodal treatment. Stage at diagnosis, resectability, response to therapy and patient condition carry greater weight than any single size measurement. Small series differ in selection and follow-up duration and do not allow a uniform prediction.
Treatment response encompasses reduction in viable tissue, control of extracardiac disease and functional improvement. Residual mass may contain necrosis and blood; size reduction may coexist with persistent infiltration. Echocardiography and MRI assess blood flow, valves, walls and pericardium, while CT mainly follows thoracic and extracardiac disease. Combined interpretation avoids assigning all clinical significance of response to a change in diameter alone.
Surveillance continues after resection and during treatment, with intervals defined by the center according to risk and disease phase. It covers the cardiac site, lungs and other involved or at-risk sites, with specific attention to the brain. New headache, seizure, hemoptysis, syncope or recurrent congestion requires earlier reassessment. In carriers of a germline predisposition, personal oncological follow-up is integrated with genetic and family care.
Recurrent tamponade, obstruction of venous return, tricuspid dysfunction and right ventricular failure are major complications. Additional problems include ischemia from coronary involvement, arrhythmias, conduction disorders and, rarely, rupture of the infiltrated wall. Thus hemodynamic deterioration may occur even without a marked increase in mass volume between examinations.
Hemorrhagic metastases can affect the lungs and brain, causing respiratory failure, hemoptysis or acute neurological events. Coexisting thrombosis requires shared decisions about anticoagulation and procedures; no single antithrombotic approach fits all disease phases. Bleeding risk also applies to biopsies and resection of metastases, which must be planned in light of the tissue's vascular nature.
After surgery, bleeding and dysfunction of reconstructed structures may occur, along with infection and arrhythmias. Systemic therapies may add myelosuppression, neuropathy and organ injury; radiotherapy may cause local toxicity. Prompt recognition allows the care plan to be adjusted while maintaining a realistic assessment of cancer benefit, cardiovascular safety and the patient's priorities.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.